摘要
目的:系统评价国内米托蒽醌治疗急性白血病的疗效。方法:计算机检索中国期刊全文数据库(1979-2010)、中国生物医学文献数据库(1989-2010),并手工检索所有纳入的参考文献,纳入米托蒽醌治疗急性白血病的随机对照试验(RCT)。评价纳入研究的方法学质量并进行资料提取后,采用RevMan4.2软件进行Meta分析。结果:共纳入5项RCT,包括341例患者。Meta分析结果显示,米托蒽醌联合化疗方案与柔红霉素联合化疗方案比较,其总有效率[RR=1.26,95%CI(1.12,1.41)]和完全缓解率[RR=1.36,95%CI(1.17,1.57)]差异均有统计学意义。结论:与柔红霉素相比,米托蒽醌能提高急性白血病治疗的总有效率和完全缓解率,但由于纳入研究样本量小,上述结论尚需要大样本、高质量的随机双盲对照试验加以证实。
To evaluate the effectiveness and safety of mitoxantrone for acute leukemia in China. METHODS： Randomized controlled trials （RCTs） of mitoxantrone for acute leukemia were collected from CNKI （1979- 2010） , CBMdise （1989--2010）. Other relevant literatures were also searched by hand. The methodological quality of the included studies was evalu- ated, and Meta-analysis were performed using RevMan 4.2 soRware. RESULTS： A total of 5 RCTs involving 341 patients were included. As for the total effective rate and complete remission rate, significant differences were found between mitoxantrone [RR= 1.26, 95 % Cl （ 1.12, 1.41 ）] vs. rubomycin [RR= 1.36, 95 % Cl （ 1.17, 1.57）]. CONCLUSION： Compared with rubomycin, treatment for acute leukemia with mitoxantrone can improve the total effective rate and the complete remission rate. However, more large-scale high-quality double-blind randomized controlled trials are required because of small-scale included samples.
出处
《中国药房》
CAS
CSCD
北大核心
2011年第12期1122-1124,共3页
China Pharmacy
